GSK 5733584
Alternative Names: GSK-5733584Latest Information Update: 01 Oct 2024
At a glance
- Originator GSK
- Class Antibodies; Antineoplastics; Drug conjugates; Immunoconjugates
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 02 Jul 2024 Phase-I clinical trials in Solid tumours (Second-line therapy or greater, Late-stage disease) in Australia (Parenteral)
- 02 Jul 2024 Phase-I clinical trials in Solid tumours (Second-line therapy or greater, Late-stage disease) in Belgium (Parenteral)
- 02 Jul 2024 Phase-I clinical trials in Solid tumours (Second-line therapy or greater, Late-stage disease) in Canada (Parenteral)